March 14, 2019
RegMed Investors’ (RMi) pre-open: be ready for a game of musical chairs of share movement
March 13, 2019
RegMed Investors’ (RMi) pre-open: uncertainty
March 12, 2019
RegMed Investors’ (RMi) pre-open: momentum to the upside returns
March 11, 2019
RegMed Investors’ (RMi) pre-open: pushing equities to the upside
March 8, 2019
RegMed Investors’ (RMi) pre-open: caution is in the air
March 6, 2019
RegMed Investors’ (RMi) pre-open: any which way is tradeable
March 5, 2019
RegMed Investors’ (RMi) pre-open: flying blind as indicators are inconsistent
March 4, 2019
RegMed Investors’ (RMi) pre-open: after every surge
March 1, 2019
RegMed Investors’ (RMi) pre-open: first trading day of March
February 28, 2019
RegMed Investors’ (RMi) pre-open: what’s on the plate?
February 27, 2019
RegMed Investors’ (RMi) pre-open: even the “beat” of street expectation, doesn’t mean much in this sector
February 25, 2019
RegMed Investors’ (RMi) pre-open: $4.3 billion or +$114.50 per share
February 22, 2019
RegMed Investors’ (RMi) pre-open: transcending to a Friday close
February 21, 2019
RegMed Investors’ (RMi) pre-open: before investors kept swept away with pricing panics
February 20, 2019
RegMed Investors’ (RMi) pre-open: the cracks in the sector
February 19, 2019
RegMed Investors’ (RMi) pre-open: a short week that’s back on the roller-coaster
February 15, 2019
RegMed Investors’ (RMi) pre-open: the known and the unknowns
February 14, 2019
RegMed Investors’ (RMi) pre-open: another missed data event as a hammer falls
February 13, 2019
RegMed Investors’ (RMi) pre-open: market actions compel focus to be on short-termism
February 12, 2019
RegMed Investors’ (RMi) pre-open: science will eventually win the battle of disease
February 11, 2019
RegMed Investors’ (RMi) pre-open: what’s new, sector anticipates Q4 and FY18 results, per share pricing losses, cash positions and “runways”
February 8, 2019
RegMed Investors’ (RMi) pre-open: oversold or overbought – when pricing reaches extreme levels, reversal are more than possible
February 7, 2019
RegMed Investors’ (RMi) pre-open: Lack of indications, quarterly results, dosing issues sow investor dissonance
February 6, 2019
RegMed Investors’ (RMi) pre-open: pressures could be brought to bear
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.